CU Cancer Center researchers are collaborating on NCI-funded research to understand the effects of psilocybin on the depression and anxiety that people with cancer can feel.
Read moreNew Psychedelic Research- Interview with a Psychiatrist
Check out this great interview with the latest research on MDMA, psilocybin, and the interaction of psychiatric medications.
Read moreHow Psilocybin May Rewire the Brain
“One of the most interesting things we’ve learned about the classic psychedelics is that they have a dramatic effect on the way brain systems synchronize, or move and groove together,” said Matthew Johnson, a professor in psychedelics and consciousness at Johns Hopkins Medicine.
“When someone’s on psilocybin, we see an overall increase in connectivity between areas of the brain that don’t normally communicate well,” Johnson said. “You also see the opposite of that – local networks in the brain that normally interact with each other quite a bit suddenly communicate less.”
Read moreMore Psilocybin Research
A recent follow-up study by Johns Hopkins Medicine researchers found two doses of the hallucinogenic compound coupled with psychotherapy resulted in large decreases in major depressive disorder symptoms for most of the study’s participants.
New research is hinting at how the hallucinogenic compound may facilitate reduced depression symptoms.
Read morePsilocybin Microdosing -New Research
Psilocybin for Depression Is Effective for One Year
New research shows that psilocybin treatment for major depression is effective for up to a year for most patients.
Read moreSSRI Drugs and Psilocybin
A new study suggests that SSRI drugs can be used safely with psilocybin to treat depression. Keep reading to learn more.
Read moreMore on Psilocybin Therapy
Psilocybin-assisted Therapy
From Johns Hopkins Psychedelic Newsletter Fall 2021:
Last year, Dr. Frederick Barrett published a study that showed psilocybin reduced neural activity in the claustrum during the period of drug action.
The claustrum, once thought to be the seat of consciousness, is a thin sheet of gray matter in the brain that reaches out to every other region in the brain.
The results showed that both the default mode network and areas of the brain believed to be responsible for setting attention and switching tasks may be disrupted during the effects of psilocybin, and alterations in the claustrum may account for these changes.
Read moreLargest Psilocybin Trial
The largest psilocybin trial to date finds the psychedelic is effective in treating serious depression.
Eagerly awaited results of the largest-ever study of psilocybin were announced Tuesday, with Compass Pathways revealing the psychedelic drug was highly efficacious as a therapy for treatment-resistant depression.
Read moreBBC Future profile on Psychedelics
By highlighting the rapid increase in psychedelic research over the past ten years, Ed Prideaux of BBC explains how clinical trial results, favorable media coverage, and the potential development of new mental health treatments are steadily moving the public perception of psychedelics toward mainstream acceptance.
"Now the efforts of Doblin and others are finally paying off,” writes Prideaux. "Promising clinical trials suggest that psychedelics may prove game-changing treatments for depression, PTSD and addiction."
Read more